Shares of The Joint Corp. (NASDAQ:JYNT) have been given a consensus recommendation of “Buy” by the six analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.15.

Several research firms have commented on JYNT. Maxim Group reissued a “buy” rating and issued a $7.00 target price on shares of The Joint in a report on Friday, August 11th. Zacks Investment Research raised The Joint from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Wednesday, September 27th.

A number of institutional investors have recently added to or reduced their stakes in JYNT. Russell Investments Group Ltd. boosted its holdings in The Joint by 24.9% in the second quarter. Russell Investments Group Ltd. now owns 87,900 shares of the company’s stock worth $334,000 after acquiring an additional 17,500 shares in the last quarter. Boston Partners boosted its holdings in The Joint by 13.1% in the second quarter. Boston Partners now owns 150,900 shares of the company’s stock worth $573,000 after acquiring an additional 17,500 shares in the last quarter. White Pine Capital LLC boosted its holdings in The Joint by 44.2% in the second quarter. White Pine Capital LLC now owns 55,500 shares of the company’s stock worth $211,000 after acquiring an additional 17,000 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in The Joint in the second quarter worth $791,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Shares of The Joint (NASDAQ:JYNT) opened at $5.27 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.21. The Joint has a 1 year low of $1.96 and a 1 year high of $6.00.

The Joint (NASDAQ:JYNT) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. The Joint had a negative return on equity of 98.28% and a negative net margin of 36.74%. The company had revenue of $6.55 million for the quarter, compared to analyst estimates of $6.28 million. equities analysts predict that The Joint will post -0.27 earnings per share for the current year.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/29/the-joint-corp-jynt-receives-average-recommendation-of-buy-from-brokerages-2.html.

The Joint Company Profile

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Receive News & Ratings for The Joint Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint Corp. and related companies with MarketBeat.com's FREE daily email newsletter.